Etoposide USP26 en es it fr

Etoposide USP26 Brand names, Etoposide USP26 Analogs

Etoposide USP26 Brand Names Mixture

  • No information avaliable

Etoposide USP26 Chemical_Formula


Etoposide USP26 RX_link

Etoposide USP26 fda sheet,%20VP-16

Etoposide USP26 msds (material safety sheet)

Etoposide_USP26 MSDS

Etoposide USP26 Synthesis Reference

No information avaliable

Etoposide USP26 Molecular Weight

588.557 g/mol

Etoposide USP26 Melting Point

236-251 oC

Etoposide USP26 H2O Solubility

58.7 mg/L

Etoposide USP26 State


Etoposide USP26 LogP


Etoposide USP26 Dosage Forms

Solution; Capsule; Liquid

Etoposide USP26 Indication

For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Etoposide USP26 Pharmacology

Etoposide is an antineoplastic agent and an epipodophyllotoxin (a semisynthetic derivative of the podophyllotoxins). It inhibits DNA topoisomerase II, thereby inhibiting DNA synthesis. Etoposide is cell cycle dependent and phase specific, affecting mainly the S and G2 phases. Two different dose-dependent responses are seen. At high concentrations (10 µg/mL or more), lysis of cells entering mitosis is observed. At low concentrations (0.3 to 10 µg/mL), cells are inhibited from entering prophase. It does not interfere with microtubular assembly. The predominant macromolecular effect of etoposide appears to be the induction of DNA strand breaks by an interaction with DNA-topoisomerase II or the formation of free radicals.

Etoposide USP26 Absorption

Absorbed well, time to peak plasma concentration is 1-1.5 hrs. Mean bioavailability is 50%.

Etoposide USP26 side effects and Toxicity

Side effects include alopecia, constipation, diarrhea, nausea and vomiting and secondary malignancies (leukemia).

Etoposide USP26 Patient Information

Patients are generally advised to call their doctor in case of fever, symptoms of infection or painful injection sites, as these may progress severely without adequate medical attention. It is advised to drink lots of fluids after treatment to prevent damage to the bladder and kidneys, typically 1.5 to 3.5 litres of water on the day of treatment and for several days after.

Etoposide USP26 Organisms Affected

Humans and other mammals